LARGE1 level in CSF enable to distinguish between SMA-cases responding and not responding to nusinersen therapy in both, adult patients (based on baseline level) and pediatric patients (based on level 180 days post-treatment). The gene discussed is LARGE1; the disease is proximal spinal muscular atrophy.